| 张 茂,闻 斌,周述银.前列腺癌组织中甲基转移样酶7B的表达及其临床价值[J].肿瘤学杂志,2021,27(3):217-221. |
| 前列腺癌组织中甲基转移样酶7B的表达及其临床价值 |
| Expression of Methyltransferase-like 7B in Prostate Cancer Tissues and Its Clinical Value |
| 投稿时间：2020-09-16 |
| DOI：10.11735/j.issn.1671-170X.2021.03.B012 |
|
 |
| 中文关键词: 前列腺癌 甲基转移样酶 7B 预后 免疫组织化学染色 |
| 英文关键词:prostate cancer methyltransferase 7B prognosis immunohistochemical staining |
| 基金项目:重庆市科委联合基金项目（2018NA03876） |
|
| 摘要点击次数: 747 |
| 全文下载次数: 191 |
| 中文摘要: |
| 摘 要：［目的］ 探讨前列腺癌组织中甲基转移样酶 7B（methyltransferase-like 7B，METTL7B）的表达水平及临床意义。［方法］ 选取武警重庆总队医院89例前列腺癌组织和60例良性前列腺增生组织，采用免疫组织化学染色法检测METTL7B表达，根据染色结果将前列腺癌患者分为高表达组和低表达组。生存分析采用Kaplan-Meier法，组间生存率比较采用Log-rank检验；采用Cox比例风险回归模型分析前列腺癌患者预后的影响因素。［结果］ 良性前列腺增生组织低表达50例、高表达10例；前列腺癌组织低表达29例，高表达60例（P＜0.05）。Ⅲ～Ⅳ期组前列腺癌的METTL7B高表达率明显高于Ⅰ～Ⅱ期组（P＜0.05），Gleason评分≥8分组的METTL7B高表达率明显高于＜8分组（P＜0.05），淋巴结转移组METTL7B高表达率明显高于未转移组（P＜0.05）。METTL7B低表达组5年总生存率为51.05%，5年无生化复发生存率为46.32%，明显高于高表达组的32.41%和18.24%（P均＜0.05）。TNM分期Ⅲ~Ⅳ期（OR=2.661，95%CI：1.409~3.897）、Gleason评分≥8分（OR=1.872，95%CI：1.314~3.008）、淋巴结转移（OR=1.573，95%CI：1.283~2.103）和METTL7B高表达（OR=3.076，95%CI：2.564~4.266）是前列腺癌患者生存时间较短的独立影响因素（P均＜0.05）。TNM分期Ⅲ~Ⅳ期（OR=1.874，95%CI：1.278~2.765）、Gleason评分≥8分（OR=1.354，95%CI：1.004~1.870）、淋巴结转移（OR=2.001，95%CI：1.497~2.775）和METTL7B高表达（OR=2.897，95%CI：2.004~4.555）是前列腺癌患者无生化复发生存时间较短的独立影响因素（P均＜0.05）。［结论］ METTL7B与前列腺癌的发生和发展有关，对预后评价有一定价值。 |
| 英文摘要: |
| Abstract：［Objective］ To explore the expression level and clinical significance of methyltransferase-like 7B(METTL7B) in prostate cancer. ［Methods］ Immunohistochemical staining was used to detect the expression of METTL7B in 89 samples prostate cancer tissue and 60 samples of benign prostatic hyperplasia tissue. The Kaplan-Meier method was used for survival analysis，and the Log-rank test was used to compare survival rates among groups. The Cox proportional hazards regression model was used to analyze the prognostic factors of prostate cancer patients. ［Results］ There were 50 cases of benign prostatic hyperplasia with low METTL7B expression and 10 cases with high METTL7B expression，while there were 29 cases with low METTL7B expression and 60 cases with high expression in prostate cancer patients(P<0.05). The high expression rate of METTL7B in stage Ⅲ～Ⅳ prostate cancer was significantly higher than that in stage Ⅰ～Ⅱ prostate cancer(P<0.05). The high expression rate of METTL7B in patients with Gleason score ≥8 was significantly higher than that in patients with Gleason score＜8(P<0.05). The high expression rate of METTL7B in patients with lymph node metastasis was significantly higher than that in patients without metastasis(P<0.05). The five-year overall survival rate and five-year biochemical relapse-free survival rate of patients with low METTL7B expression were significantly higher than those in patients with high METTL7B expression(51.05% vs. 32.41% and 46.32% vs. 18.24%，respectively; both P<0.05). TNM staging Ⅲ~Ⅳ(OR=2.661，95%CI：1.409~3.897)，Gleason score≥8 points(OR=1.872，95%CI：1.314~3.008)，lymph node metastasis(OR=1.573，95%CI：1.283~2.103) and high expression of METTL7B(OR=3.076，95%CI：2.564~4.266) were independent risk factors for shorter survival time of prostate cancer patients(P<0.05). TNM staging Ⅲ~Ⅳ(OR=1.874，95%CI：1.278~2.765)，Gleason score ≥8 points(OR=1.354，95%CI：1.004~1.870)，lymph node metastasis(OR=2.001，95%CI：1.497~2.775) and the high expression of METL7B(OR=2.897，95%CI：2.004~4.555) were independent factors influencing the shorter survival time of prostate cancer patients without biochemical recurrence(all P<0.05). ［Conclusion］ METTL7B expression is up~regulated in prostate cancer，and it has certain value in evaluating the prognosis of patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |